Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Long-Term Extension Study to Assess the Safety and Efficacy of Etanercept in the Treatment of Psoriasis in Adult Subjects
Brief Summary: The objective of the study is to describe the safety, tolerability, and efficacy of the long-term administration of etanercept in adults with psoriasis who have completed etanercept psoriasis study 20030115 or 20030117, in Canada, and are continuing in a long-term extension. Subjects from the 20030115 study will be followed for 24 months which began in Oct. 2004. Subjects in the 20030117 study will be followed for 12 months which began in mid 2005.


Options:
A: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
B: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
C: Arm Label: Part 1: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 2: Tildrakizumab 5 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 25 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 2: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Biological: tildrakizumab | Arm Label: Part 3: Tildrakizumab 5 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 25 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 100 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Tildrakizumab 200 mg Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Part 3: Placebo Follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: tildrakizumab; Assigned to Arm(s): Part 1: Tildrakizumab 100 mg, Part 1: Tildrakizumab 200 mg, Part 1: Tildrakizumab 25 mg, Part 1: Tildrakizumab 5 mg, Part 2: Tildrakizumab 100 mg, Part 2: Tildrakizumab 200 mg, Part 2: Tildrakizumab 25 mg, Part 2: Tildrakizumab 5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo
D: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A